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Despite having a rich history as a poison, arsenic and its
compounds have also gained a great reputation as pro-
mising anticancer drugs. As a pioneer, arsenic trioxide has
been approved for the treatment of acute promyelocytic
leukemia. Many in vitro studies suggested that arsenic tri-
oxide could also be used in the treatment of solid tumors.
However, the transition from bench to bedside turned out to
be challenging, especially in terms of the drug bioavail-
ability and concentration reaching tumor tissues. To ad-
dress these issues, nanomedicine tools have been
proposed. As nanocarriers of arsenic trioxide, various ma-
terials have been examined including liposomes, polymer,
and inorganic nanoparticles, and many other materials. This
review gives an overview of the existing strategies of de-
livery of arsenic trioxide in cancer treatment with a focus
on the drug encapsulation approaches and medicinal im-
pact in the treatment of solid tumors. It focuses on the
progress in the last years and gives an outlook and sug-
gestions for further improvements including theragnostic
approaches and targeted delivery.
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1 | INTRODUCTION
“The King of Poisons”1 or a “magic bullet”2—the attributes researchers have given arsenic trioxide (ATO) in the
course of its use in medical treatment reflect its paradoxical properties. Indeed, ATO has been described as healing
and killing, as cancerous and anticarcinogenic, as an environmental toxin, and a novel chemotherapeutic. In the
following, we want to shed some light on the double‐edged sword ATO represents and on the most recent scientific
approaches to use nanoparticles as an attempt to make the remedy outweigh the poison.
1.1 | From panacea to first line therapy of APL
In traditional Chinese medicine, ATO has been used for hundreds of years as a remedy for various diseases such as
fever, infectious, or rheumatic disease.2,3 In western medicine, Fowler solution (arsenite potassium) was used
between the 18th and mid‐20th century to treat a broad range of diseases such as asthma, cholera, syphilis, and
hematological diseases like anemia, leukemia, and Hodgkin's disease.1–3 As early as 1878, Cutler and Bradford
described the effect of Fowler solution on white blood cells. In their case series, two healthy individuals and one
patient with leukemia responded to arsenic treatment with a decrease in leukocytes, which was dramatic in
the latter.4 The emergence of roentgen therapy for leukemia at the beginning of the 20th century eviscerated the
use of arsenite potassium until the case series of Forkner and Stephens in the 1930s discussed it as effective
palliative therapy for chronic myeloid leukemia (CML).5,6 The observed toxicity was described as mild and re-
versible.6 Even though other authors did not dispute the efficacy of arsenic potassium in the treatment of CML,
more cautious voices arose given the observation of sequelae like ceratosis, liver cirrhosis, or polyneuritis after
long‐term treatment.7 Eventually, conventional chemotherapy displaced arsenic in the treatment of leukemia.2 It
was not until the late 20th century that ATO regained interest as a therapeutic agent for leukemia when Chinese
researchers evaluated it for therapy of acute promyelocytic leukemia (APL). The studies conducted showed ex-
ceedingly high remission rates ranging from 72.7% to 90%.8–10 The American Food and Drug Administration (FDA)
acknowledged the efficacy of ATO for APL treatment with approval for relapsed and refractory APL in 2000,11
followed by the European admission 2 years later.12 Direct binding of the promyelocytic leukemia protein—retinoic
acid receptor alpha (PML‐RARα) oncogene leading to degradation was identified as a mean mechanism of action of
ATO in PML.13 Two key multicenter, randomized, controlled Phase III studies showed that the combination therapy
of ATO and all‐trans‐retinoic acid (ATRA) was superior to conventional chemotherapy in terms of improved event‐
free survival and relapse rate, with adverse effects that were controllable and reversible with the suspension of
treatment.14,15 Subsequently, the admission of ATO got extended to newly diagnosed APL12,16 and today, the
combination therapy of ATO‐ATRA is state of the art for APL treatment.
1.2 | ATO for treatment of solid tumors and drawbacks of ATO in clinical use
Even though the binding and degradation of PML‐RARα is considered the main mechanism of action of ATO in APL,
studies have elucidated that ATO sensitivity in APL is not merely mediated by PML‐RARα expression.17 Other
mechanisms for ATO in APL such as generation of reactive oxidative species (ROS),17 activation of C‐Jun
N‐terminal kinase,18 and induction of apoptosis associated with the downregulation of bcl‐2 protein9 have also
been described. These observations, combined with the clinical success of ATO in APL treatment, have led to an
advancing interest to evaluate the effects of ATO in, and to make it utilizable for, other malignancies as well. Indeed,
the preclinical studies of ATO in other hematologic and solid tumor entities are promising as ATO turned out to
induce apoptosis and inhibit proliferation in several malignant hematologic and solid tumor entities. Interestingly,
a recent study by Chen et al.19 identified ATO as capable of rescuing structural p53 mutants in cell lines derived
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from hematological as well as solid malignancies, highlighting the broader potential of ATO as an anti‐tumorigenic
drug. Other mechanisms identified include, but are not limited to, induction of caspase‐3,20 generation of ROS,21
alteration of the cell cycle,22,23 reduction of stem cell markers,24 and inhibition of glioma‐associated oncogene
family zinc finger (GLI) transcription factors.25–27
The first clinical Phase II studies evaluating the efficacy of ATO in solid tumors were initiated at the end of the
last millennium.28 Over the past 20 years, patients with different tumor entities such as hepatocellular carcinoma,
glioblastoma, or lung cancer were treated with different therapy regimes of ATO alone or in combination therapy.
A number of ongoing clinical trials evaluating ATO in solid tumors are registered at https://www.clinicaltrials.gov/
(i.e., in neuroblastoma—ClinicalTrials.gov number NCT03503864 and malignant glioma—ClinicalTrials.gov number
NCT00275067). The results of those studies are still pending.
While some patients in the Phase II studies conducted showed stable disease29,30 or partial remission,29 no
general clinical response could be observed upon ATO treatment31,32 (see Subbarayan & Ardalan33 for a review).
On the contrary, severe adverse events (≥Grade 3) were described in the majority of clinical trials.29–32,34–36
Although the adverse events were deemed as moderate and well‐tolerated in a number of studies,29,32,35,36 in other
studies, side effects attributable to ATO lead to Grade 5 events31 and treatment29 respectively study dis-
continuation37 in patients with solid tumors.
Well‐known adverse effects of ATO, not only in patients with solid tumors but in APL patients as well, are QTc
prolongation,15,38 dermatological conditions like rashes or hyperkeratosis,7,29 neurotoxicity,15 and transaminase
elevation.14,15 What is more, the carcinogenic potential of arsenic compounds has been pointed out (see Martinez
et al.39 for a review) and carcinogenicity of ATO is considered an “important potential risk” by the European
Medicines Agency (EMA).12
The poor clinical outcome in solid tumors stands in contrast to the antiproliferative, proapoptotic effect of ATO
in many solid cancers in preclinical in vitro and in vivo models. For this circumstance, different explanations are
conceivable. First, as APL is a hematologic malignancy, intravenously administered ATO is located where it needs to
act: in the blood. It does not need to accumulate at a specific tumor site nor pass the blood–brain barrier (BBB), as it
does when acting on a solid (brain) tumor. Therefore, insufficient concentrations of ATO reaching the tumor site are
considered the main obstacle in the treatment of solid tumors.40 Second, a priori or acquired resistance towards
ATO has been described in APL patients41–43 and seen in solid tumor cell lines44,45 and is likewise imaginable in
solid tumors in the clinic.
1.3 | Nanoparticles as an approach to overcome the shortcomings of ATO
in solid tumors
In recent years, the advent of nanoparticles as novel drug delivery systems (DDSs) has offered new possi-
bilities for improved delivery of chemotherapeutic drugs, for example, by increasing their bioavailability,
decreasing their effects on healthy tissue, or enhancing their uptake by tumor cells (see Sun et al.46 for a
review). Utilizing DDSs for ATO delivery has been proposed as an efficient tool to eliminate some of the
drawback of ATO use in therapy, such as (i) rapid clearance of ATO and its products from the blood,47 and (ii)
low specificity. Due to rapid clearance, a therapeutic dose of ATO is not reaching the tumor sites and a simple
dosage increase of ATO is not feasible due to its systemic toxicity. However, utilizing DDSs offers an
attractive approach to foster the antitumor effects of ATO and to possibly overcome the limitation of the
insufficient enrichment at the tumor side while reducing its adverse effects. Moreover, nanotechnology
offers the possibility of tailoring the DDDs to target different types of solid cancers specifically, for instance,
by attaching specific targeting ligands to the carrier surface.
Different strategies of ATO delivery to solid tumor entities have been examined over the past several years.
They differ regarding the encapsulation strategies, the kind of carrier material used and the type of tumor the
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ATO‐formulation aim to target. In this review, we focus on the newest development over the last few years and
highlight some of the older studies, which were reviewed previously.48
2 | STRATEGIES OF ATO ENCAPSULATION
ATO (As2O3) is an amphoteric oxide (i.e., a compound able to react both as a base and as an acid) and its aqueous
solutions are weakly acidic (H3AsO3). ATO dissolves readily in alkaline solutions and forms arsenites with the
following pKa values: H2AsO3
− (pKA1 = 9.22), HAsO3
2− (pKA2 = 12.10), and AsO3
3− (pKA3 = 13.40).
49 To encapsulate
ATO into a drug vehicle effectively, different strategies have been reported. These include: (i) reaction of ATO with
transitions metals [M; such as Ni(II), Co(II), Zn(II), Mn(II), and Pt(II)] to form insoluble MAsOx complexes, (ii) binding
ATO to thiol or amino functional groups, and (iii) anionic exchange. The different strategies utilized for different
DDSs are summarized in Tables 1 and 2 and discussed in detail in the following chapter.
3 | MATERIALS USED AS DDSs OF ATO
DDSs can be classified based on the type of material which forms the nanocarrier as organic, inorganic and hybrid.
Each of these groups has its advantages and disadvantages. For instance, liposomes often feature a low drug
loading capacity and instability during storage. Meanwhile, mesoporous silica nanoparticles (MSNs) can load the
drug efficiently due to the porous structure and extremely high specific surface area, but often exhibit a high burst
drug release during systemic circulation. The pros and cons of each material class are shown and discussed in the
text below.
3.1 | Organic
DDSs of ATO based on organic materials are summarized in Table 1 and include liposomes, proteins, dendrimers,
and polymer nanoparticles.
3.1.1 | Liposomes
One of the first DDSs investigated for ATO delivery were liposomes.79–81 Liposomes are spherical vesicles, which
compose an internal aqueous cavity surrounded by a bilayer usually made of phospholipids. The hydrophobic lipid
membrane can encapsulate strongly lipophilic drugs, whereas the hydrophilic interior can entrap water‐soluble
molecules such as ATO. However, there are two main drawbacks when using liposomes for ATO delivery—low
carrier stability and diffusivity of ATO through the membrane, both resulting in an immature drug release. To
address the issues, two main strategies have been proposed—utilizing liposomes based on arsenic contacting lipids
(=arsonolipids)80,81 and ATO loading in presence of transition metal ions.82,83
When ATO is loaded into liposomes, the neutral As(OH)3 molecules (which are predominant at pH< 9.0) diffuse
readily across the phospholipid membrane making the drug entrapment difficult. To overcome this issue, an en-
capsulation employing transmembrane gradients of transition metal ions (e.g., Ni(II), Co(II), Zn(II), and Pt(II)) to
produce insoluble complexes with As(III) was proposed in 200682 and extensively studied in the later years. As
described by Chen et al.,82 to form the DDS, a liposome is first loaded with a salt of the transition metal (e.g.,
acetate), then ATO is added. During the cycle of loading ATO into a liposome, the neutral As(OH)3 diffuses across
the lipid membrane and reacts with the metal(II) ions to form insoluble metal(II) arsenite complexes inside the






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































SÖNKSEN ET AL. | 381
liposome. During the reaction, protons are released, which react with acetate ions to form acetic acid. Conse-
quently, the weak acid diffuses out of the liposome in exchange for ATO. Both the formation of insoluble metal(II)
arsenite complexes and the efflux of acetic acid facilitate the ATO uptake and entrapment in a liposome (Figure 1).
For such systems of drug encapsulation in liposomes, the term “nanobin” (NB) was proposed.82 For instance, it was
shown that nanobin encapsulation of ATO (NB(Ni, As)) significantly improved pharmacokinetic properties of the
drug and led to greater therapeutic efficacy compared with free ATO in an orthotopic model of triple‐negative
breast cancer.84 In a follow‐up work, the nanobins (NB(Ni, As)) were coated with a pH‐sensitive polymer to enable
pH‐triggered drug release.85 Nanobins were also used for co‐encapsulation of arsenic and platinum drugs.83
Liposomes can be also functionalized with various targeting ligands to enable ATO delivery to specific cells. For
instance, ATO‐loaded liposomes were functionalized with folate ligands and their cellular uptake and antitumor
efficacy were evaluated in folate receptor (FR)–positive human nasopharyngeal epidermal carcinoma (KB) and
human cervical carcinoma (HeLa) cells, as well as FR‐negative human breast carcinoma (MCF‐7) cells.86 The uptake
of folate functionalized ATO‐loaded liposomes by KB cells was three to six times higher than that of free ATO or
liposomes without the targeting ligands. Zhang et al.87 reported on nanobins (NB(Ni, As)) functionalized with
urokinase plasminogen activator antibodies to promote targeted delivery to epithelial ovarian cancer cells (in which
the urokinase system is overexpressed compared to normal cells). The targeted nanobins showed a fourfold higher
uptake in ovarian cancer cells in comparison with nontargeted nanobins.
In the last years, delivering ATO using liposomes has also been studied to examine whether liposomal‐
encapsulated ATO could reduce the drug toxicity and improve the efficacy of ATO in treating human papillomavirus
(HPV)‐associated cancers. Wang et al.50 showed that ATO encapsulated into liposomes in presence of Ni(II) ions
induced apoptosis and reduced protein levels of HPV‐E6 in HeLa cells more effectively than ATO alone. Akhtar
et al.51 altered the properties of liposomes such as size (from 100 to 400 nm) and surface charges and studied their
influence on the efficiency of ATO delivery to cervical cancer cells. It was shown that neutral liposomes of 100 nm
in size were the best‐tested formulation, as they showed the least intrinsic cytotoxicity and the highest loading
efficiency.
When Mn(II) ions are used as transitions metal to efficiently encapsulate ATO inside a liposome, drug nano-
carrier suitable for magnetic resonance imaging (MRI), and thus theragnostic applications, can be prepared
(Figure 1).52 The formation of the Mn(II) arsenite precipitate in liposomes generates magnetic susceptibility effects,
which can be detected as a dark contrast on T2‐weighted MRI. When accepted by cells, due to a low pH in
endosome‐lysosome, the Mn(II) arsenite complex decomposes, which results in a release of the As‐drug and Mn(II)
ions (i.e., a T1 contrast agent that gives a bright signal in MRI). The convertible MRI signals (dark to bright) enable to
follow not only the ATO delivery but also its release. Moreover, the liposomes were functionalized with phos-
phatidylserine (PS)‐targeting antibodies to enable a specific binding of the nanodrug to PS‐exposed glioma cells.
F IGURE 1 Schematic illustration of the preparation of liposomal nanocarrier of arsenite‐manganese
functionalized with targeting ligands. (Figure adapted from Zhang et al.52) [Color figure can be viewed at
wileyonlinelibrary.com]
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3.1.2 | Proteins
Zhou et al.88,89 investigated albumin as a DDS for ATO. Albumin microspheres as a DDS for ATO were prepared
using a chemical crosslink and solidification method and the synthesis was optimized with regard to the particle size
and drug loadings.88 In another work, ATO‐loaded albumin microspheres were functionalized with a trans‐
activating transcriptional activator peptide (i.e., a cell‐penetrating peptide) and the nano drug delivery into bladder
cancer cells was evaluated.89 The results indicated that the attached peptide enhanced intracellular permeation of
the nano drug by translocating microspheres across the cell membrane.
3.1.3 | Polymers
Nanoparticles based on several different polymers have been proposed as DDSs for ATO. These polymers include
polylactic acid (PLA),53 poly(lactide‐co‐glycolide) (PLGA),54–57,90 sodium alginate,58 polyamidoamine (PAMAM)
dendrimer,59 pluronic F127 polymer,91 or chitosan.92
Polymeric nanoparticles as DDSs of ATO are often prepared by a double emulsion (water‐in‐oil‐in‐water =
w/o/w) solvent evaporation/extraction method. In the method, a polymer is dissolved in an organic solvent to form
the organic phase. Then an aqueous phase containing ATO is emulsified into the organic phase by ultrasonication to
form a primary emulsion, which is then added to an aqueous solution of a surfactant. The mixture is then stirred
open to the air to evaporate the organic solvent and make the nanoparticle. This method was utilized, for instance,
to prepare polylactic acid (Figure 2) or poly(lactide‐co‐glycolide) nanoparticles discussed in the following text.
Song et al.53 used the double emulsion (w/o/w) solvent‐evaporation method (Figure 2) to prepare ATO‐loaded
polylactic acid/magnetic nanoparticles. They studied the preparation conditions in detail to optimize the en-
capsulation efficiency and particle size distribution. It was shown that the ATO‐nanoparticles (ATO‐NPs) attached
easily to hepatocellular carcinoma (HCC) cell line SMMC‐7721 and had higher inhibition efficiency on SMMC‐7721
cells than free ATO.
Another polymer examined as DDS for ATO was poly(lactide‐co‐glycolide) (PLGA).90 Su et al.54 reported
on ATO‐loaded PLGA nanoparticles cloaked by red blood cell membrane (RBCM) (Figure 3) to reduce their
cytotoxicity as they demonstrated on the human embryonic kidney cell line 293T. Song et al.56 coated PLGA
nanoparticles with polyethylene glycol (PEG) and/or lactobionic acid to improve the carrier biocompatibility.
In a follow‐up study, they used PLGA nanoparticles coated with PEG and lactobionic acid modified chitosan
for encapsulation and targeted release of ATO in liver cancer treatment.57 The ATO‐NPs showed only low
cytotoxicity against normal human liver cells (LO2 cells) but effectively inhibited SMMC‐7721 cells. Similar
results were obtained also in in vivo studies, in which the NPs did not show toxic effects on kidney and liver,
but could inhibit the growth of liver tumor. Hu et al.55 also reported on ATO‐loaded PLGA nanoparticles for
HCC treatment. To evaluate the anticancer effects, HCC cell lines Huh7 and Bel‐7402 were used. It was
F IGURE 2 Synthesis route to arsenic trioxide (ATO)‐loaded polylactic acid (PLA)/magnetic nanoparticles.
(Figure reprinted with permission from Song et al.53) [Color figure can be viewed at wileyonlinelibrary.com]
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reported that the nano drug had a better inhibition and promoted greater lactate dehydrogenase release in
comparison to free ATO. In vivo the ATO‐NPs induced a significant decrease in the expression of DNA
methyltransferases, while the expression of N‐terminal‐cleaved gasdermin E was upregulated. As a con-
sequence, the nanoparticles inhibited the tumor growth more than free ATO or a control.
Lian et al.58 reported on sodium alginate nanoparticles (SANs) as a DDS for ATO. ATO‐loaded SANs were
prepared by the ion crosslinking method and were subsequently camouflaged with RBCM. The ATO‐NPs had
lower cytotoxicity than ATO on normal 293 (kidney) cells and exhibited antitumor effects on both NB4 (PML)
cells and SMMC‐7721 (HCC) cells. Moreover, it was shown also in in vivo studies that the ATO‐NPs reduced
the drug toxicity and improved the antitumor effects in comparison to ATO which caused mild lesions of main
organs.
Lu at al.59 reported on a pH‐responsive dendrimer based on polyamidoamine (PAMAM) as a DDS of ATO.
The surface of the nanoparticles was functionalized with an αvβ3 integrin targeting ligand to enable targeted
delivery to glioma. In in vitro BBB model, the targeting ligand attachment heightened the cytotoxicity of the
ATO‐loaded nanoparticles, due to an increased uptake by C6 (glioma) cells. In vivo, the tumor volume of C6
glioma‐bearing rats was reduced by 61.5 ± 12.3% after intravenous administration of the nano drug, and that
was approximately fourfold higher than that of free ATO and twofold higher than that of the nano drug
without the targeting ligands.
F IGURE 3 Synthesis route to arsenic trioxide (ATO)‐loaded poly(lactide‐co‐glycolide) (PLGA) nanoparticles
cloaked by red blood cell membrane (RBCM). (Figure adapted with permission from Su et al.54). NP, nanoparticle
[Color figure can be viewed at wileyonlinelibrary.com]
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3.2 | Inorganic nanoparticles
As inorganic carriers, two types of materials were intensively studied—materials based on metal (or metal oxide)
nanoparticles and silica nanoparticles. The overview of inorganic DDSs for ATO is given in Table 2.
3.2.1 | GdAsOxnanoparticles
As metal nanoparticles for ATO delivery, GdAsOx NPs were proposed. To synthetize such nanodrug, Chen et al.
60
co‐precipitated As with Gd in the presence of dextran into GdAsOx NPs. It was proposed that the unloading of ATO from
such nanoparticles could be triggered by endogenous phosphate ions present in the plasma and cytosol. In the release
process, the arsenite ions would be exchanged by phosphate ions, and thus ATO release could be achieved. Indeed, the in
vitro results showed that the nanoparticles gradually “dissolved” into fragments in a phosphate solution. In follow‐up
studies, the therapeutic effect of GdAsOx NPs on aggressive HCC was studied.
61,93 After administration of the ATO‐NPs,
arsenic accumulation within tumors was evaluated. It was found that the accumulation of the ATO‐NPs was as much as
5%, which was ten times more than when only ATO was administrated.61 Additionally, it was shown in a series of in vitro
and in vivo experiments that after the administration of ATO‐NPs, the phosphate concentration decreased, and as a
consequence, the corresponding pH increased. Thus, exhausting the phosphate ions resulted in neutralizing the tumor
acidity. Zhao et al. reported on dextran coated GdAsOx NPs for chemoembolization therapy of the rabbit VX2 liver
tumor.62 The nanoparticles were studied both in vitro and in vivo, and the results showed that the ATO‐NPs caused severe
necrosis via chemoembolization combinational therapy.
3.2.2 | Mesoporous silica nanoparticles
Nanoparticles formed by mesoporous silica have been extensively studied as DDSs not only for ATO.94 MSNs are a class
of inorganic porous material, which comprise open mesoporous channels with a diameter of 0.1–10nm. Furthermore, their
outer surface can be modified by attaching various molecules including targeting ligands for tumor specific drug delivery.
The high material porosity enables high drug loading. However, due to nonspecific drug–material interactions, a burst drug
release is often observed. To decrease the burst release and increase ATO loading, two main strategies were reported
(Figure 4A,B). First, enhanced ATO binding via thiol63,64 or amino functional groups65,66 anchored on the surface of the
mesoporous channels, and second—similar to the strategy for liposomes described above—an encapsulation of ATO in
presence of transition metal ions to form insoluble MAsOx complexes.
67–70 To increase the ATO loading even more, the
second approach was applied to hollow MSNs (Figure 4C).71–73
Thiol group and amino group functionalized MSNs
Silica nanoparticles functionalized with thiol groups were used to bind ATO to develop nano drug for treating MDA‐MB‐
231 triple‐negative breast cancer (TNBC).63 The inner and outer surfaces of MSNs were functionalized with thiol groups
not only for the ATO binding, but also to conjugate targeting agents to the outer surface. As a targeting ligand, cyclic
peptide Arg‐Gly‐Asp‐D‐Phe‐Lys (cRGDfK) was used. Human TNBC cells showed a higher uptake of ATO‐MSNs which
were functionalized with the targeting ligands compared to nontargeted ATO‐MSNs. Moreover, it was shown in vivo in a
mouse model of human TNCB, that the ATO‐MSNs with targeting ligands effectively inhibited a tumor growth at a low
ATO dosage of 0.75mg/kg. Ellison et al.64 reported on MSNs decorated with thiol functional groups as carriers of
radioisotopes of [*As]arsenic trihydroxide (∗=72, 76, 74, 71). The idea was to combine the chemotherapeutic effects of
ATO with positron emission tomography (PET) of [*As] for image‐guided drug delivery.
Xiao et al.65 reported on amino group functionalized MSNs capped with polyacrylic acid (PAA) for pH‐trigged
ATO release in acidic microenvironment of tumor. The antitumor efficacy of the ATO‐NPs was investigated both in
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vitro (SMMC‐7721 cell line) and in vivo (H22 xenografts). Similarly, also Tao at al.66 proposed MSNs decorated with
amino functional groups for pH‐triggered ATO delivery. They reported on angiopep‐2‐conjugated core−shell
silica‐liposome hybrid nanovesicles for targeted and pH‐triggered delivery of ATO to glioma. By performing a
blood−glioma microdialysis, the targeting efficiency of the ATO‐NPs was evaluated. Moreover, the improved
glioma‐specific distribution of ATO and its antitumor effects in comparison with free ATO could be shown both in
vitro and in vivo.
MSNs with MAsOx complexes
To prepare silica nanoparticles with MAsOx complexes, two approaches were reported (Figure 4B)—(i) loading pre‐
synthesized MSNs with a transition metal salt and subsequently with ATO,67 and (ii) pre‐synthesizing MAsOx
nanoparticles and coating them subsequently with a shell of mesoporous silica.68–70 The advantage of the first
approach is that the MSNs can be combined with other nanoparticles before ATO is loaded. For instance, MSNs
were combined with magnetic iron oxide nanoparticles to enable not only ATO delivery but also real‐time
F IGURE 4 Schematic illustration of different synthesis approaches to prepare silica‐based nanoparticles for
arsenic trioxide (ATO) delivery [Color figure can be viewed at wileyonlinelibrary.com]
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monitoring via MRI, and thus a theragnostic function.67 As a drug, ATO prodrug (NiAsOx) was loaded into the
mesopores. The surface of the nanoparticles was functionalized with folic acid as a targeting ligand to enhance
the drug efficacy in treatment of HCC. The superior antitumor activity of the magnetic ATO‐NPs in comparison to
free ATO was confirmed by in vitro experiments with SMMC‐7721 cells as well as by in vivo experiments with mice
bearing H22 tumors. Moreover, the imaging ability of the magnetic nanodrug for real‐time tumor monitoring by
MRI was shown.
Another theragnostic agent combining ATO delivery and MRI was reported by Zhang et al.,68 who developed
MnAsOx@SiO2 core‐shell nanoparticles. In the synthesis, first manganese arsenite complexes were prepared by a
co‐precipitation of manganese acetate and aqueous ATO. Then tetraethyl orthosilicate was added to coat the
MnAsOx nanocomplexes with a silica shell. In a subsequent step, the nanoparticles were decorated with a pH‐low
insertion peptide (pHLIP), which was added to target an acidic tumor microenvironment. The targeting ability was
confirmed in in vivo experiments with BALB/c mice, which further revealed that pHLIP could also considerably
prolong the circulation time of the nano drug. Moreover, the released Mn(II) ions brighten the T1 signal in MRI,
which could be used for real‐time monitoring of the chemotherapy treatment.
Huang et al.69 reported on ZnAsOx@SiO2 NPs. In the synthesis, firstly ZnAsOx complexes were prepared, which
were subsequently encapsulated in a SiO2 matrix. The antitumor activity of the ATO‐NPs was investigated in vitro
with HCC cell lines (MHCC97L and Hep3b). In comparison to free ATO, the ATO‐NPs promoted apoptosis and
significantly inhibited proliferation, migration, and invasion of both tested cell lines. In in vivo experiments, the
ATO‐loaded NPs inhibited tumor growth by 2.2‐fold and metastasis by 3.5‐fold more than free ATO. Liu et al.70
reported on a dual‐drug loading, including ATO and doxorubicin (DOX), into MSNs and demonstrated a drug
synergy and pH‐triggered drug release for effective treatment of DOX resistant HCC cells. First, FeAsOx nano-
particles were prepared, followed by in situ coating with an amine‐functionalized silica shell. Subsequently, DOX
molecules were anchored on the nanoparticles by pH‐sensitive imine bonds. It was shown that such NPs could
enhance drug accumulation and cytotoxicity in DOX‐resistant HuH‐7/ADM cells.
Hollow silica nanoparticles
To increase the ATO loading capacity of MSNs even more, hollow silica nanoparticles (HSNs) were investigated as
DDSs.71–74 Zhao et al.71 prepared HSNs via selective etching of Fe3O4@SiO2‐NH2 with HCl. To introduce the drug,
first the HSNs were treated with an aqueous nickel acetate solution, and then an aqueous ATO solution was used to
prepare water‐insoluble nickel arsenite complexes (=ATO prodrug) encapsulated inside the nanocarrier. To enable
targeted delivery, epidermal growth factor receptor (EGFR)‐Affibody molecules were attached to the carrier sur-
face. The anticancer activity of the ATO‐NPs was studied on four different cell lines (HeLa, RAW 264.7, HepG2,
and SMMC‐7721). Moreover, in vivo therapeutic study in mice bearing mouse hepatoma H22 tumors were carried
out. Notably, the ATO‐NPs were more effective in inhibiting tumor growth in comparison to free ATO. The authors
discussed that this observation might be attributed to the possible ability of nanoparticle formulation to reduce
renal clearance of ATO and an improved drug accumulation at the tumor site by the enhanced permeability and
retention (EPR) effect.95
In another work, HSNs loaded with ATO in the presence of Mn(II) ions were examined in the treatment of
HCC.72 It was shown that the ATO‐NPs could decrease the invasion of HCC cells not only in vitro but also in vivo
without adverse side effects (determined by pathology tests of the main organ tissues). Zhao et al. demonstrated
that HSNs containing manganese arsenite complexes could be used as a pH‐sensitive multifunctional DDS capable
of real‐time monitoring of ATO release by activatable T1 imaging in MRI (Figure 5). It was shown that in acidic
environment, the simultaneous release not only of ATO but also of manganese ions was triggered. Subsequently,
the released manganese ions increased the T1 signal (bright signal) in MRI and thus, real‐time visualization and
monitoring of ATO release and delivery could be achieved. To functionalize the nanocarrier surface, glutathione
(GSH) was used. The anticancer activity of the nano drug was studied both in vitro (HeLa, HepG2, SMMC‐7721, and
H22 cells) and in vivo (BALB/c mice and nude mice bearing human HCC tumors).
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Fei et al.74 prepared hybrid core‐shell nanoparticles by coating HSNs (functionalized with amino groups) with a
liposomal shell for controlled ATO release. The surface of the nanoparticles was functionalized with Arg‐Gly‐Asp
(RGD)‐ligands to enable targeted delivery. In vitro, the ATO‐NPs showed good biocompatibility and low toxicity on
HepG2, MCF‐7, and LO2 cells. Moreover, due to the attached ligand, enhanced cellular uptake and a reduced half‐
maximal inhibitory concentration (IC50 value) of the nano drug could be detected. In addition, the targeting effi-
ciency of the ligand functionalized ATO‐NPs was also confirmed in an H22 tumor‐xenograft mouse model.
3.3 | Hybrid
Hybrid materials consist of at least two constituents at the nanometer or molecular level. Commonly one of these
components is inorganic and the other one organic in nature. Many of the materials discussed in the two previous
chapters (organic and inorganic materials) and summarized in Tables 1 and 2, could be considered as hybrid or
composite materials by the composition. For instance, inorganic nanoparticles coated with an organic polymer
(to improve the nanocarrier's biocompatibility) or organic targeting ligands (to enable targeted delivery), or inorganic
and organic particles combined with magnetic nanoparticles (to enable detection via MRI). However, these DDSs
were already included in the previous chapters based on the type of the carrier material (either organic or inorganic)
which was used for the ATO encapsulation. From this point of view, as a typical hybrid material, only metal‐organic
frameworks (MOFs) are considered in this section.
3.3.1 | Metal‐organic frameworks
MOFs are porous crystalline coordination polymers. They comprise inorganic metal ions (or clusters) and organic
ligands.96 They exhibit outstanding properties including high internal surface area and chemical versatility. They
have been suggested as promising materials for many different applications including gas storage, catalysis, and
sensing,97 but also drug delivery.98 The most prevalent method described in published reports to capture drug
molecules in MOFs is via noncovalent interactions.98 In such cases, upon administration, the drug can easily diffuse
from the material, and thus no control over the release is achieved. However, when administrating toxic drugs such
as ATO, having a control of the drug release is crucial. Therefore, for ATO delivery, MOFs having possibilities to
form a strong interaction with ATO, such as a chemical bond, were proposed and are summarized in Table 2.
F IGURE 5 Schematic illustration of HSNs loaded with ATO and its drug release with activatable T1 imaging
process inside cells enabled by released Mn(II)ions. (Figure reprinted with permission from Zhao et al.73)
[Color figure can be viewed at wileyonlinelibrary.com]
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The first MOF reported for ATO delivery was MFU‐4l (MFU stands for Metal‐Organic Framework Ulm Uni-
versity).75 MFU‐4l consists of Zn(II) ions and bis(1H‐1,2,3‐triazolo[4,5‐b],[4ʹ,5ʹ‐i])dibenzo[1,4]dioxin (H2‐BTDD) as a
ligand. In the framework structure, [Zn5Cl4(BTDD)3], there are negatively charged chloride side ligands, which were
shown to be postsynthetically exchangeable to arsenite ions. Cytotoxicity studies conducted on atypical teratoid/
rhabdoid (ATRT) cell lines revealed that the ATO‐NPs had similar effects on cancer cell lines as free ATO).75 In
another work, Ettlinger et al.76 showed that a MOF called ZIF‐8 (ZIF stands for zeolitic imidazole framework) could
be an even more promising candidate for ATO delivery. Not only that it enables a high drug loading capacity (due to
its high porosity), but additionally, due to pH‐sensitive Zn–N coordinate bonds, a pH‐triggered drug release can be
achieved. Moreover, in in vitro cytotoxicity studies the ATO‐ZIF‐8 nanoparticles had a substantial cytotoxic effect
on tested ATRT cell lines at low concentrations and the cytotoxic effect was similar to free ATO. In a related work
reported by Ettlinger et al.,77 ZIF‐8 nanoparticles were combined with superparamagnetic iron oxide (Fe3O4)
nanoparticles, which are common contrast agents used in MRI. A shell of ZIF‐8 was grown around nanosized Fe3O4
clusters to prepare a core‐shell structure, in which the core would be responsible for imaging via MRI, whilst the
shell could function as DDS for treatment of ATRT. Both the imaging and therapeutic activity were demonstrated
in vitro.
Another reported MOF for ATO delivery, which also displayed a prominent pH‐triggered behavior, was
Zn‐MOF‐74.78 Zn‐MOF‐74 consists of Zn(II) ions and 2,5‐dihydroxybenzene‐1,4‐dicarboxylate ligands and when
desolvated, it contains a high density of vacant metal sites readily accessible for guest binding. It was shown that
ATO could be successfully attached to these sites, and thus a high drug loading could be achieved. Moreover, it has
been shown that the drug release, tested in a phosphate buffered saline, could be triggered by a pH change from
7.4 to 6.0. However, no additional biological studies have been reported.
4 | BENEFITS OF UTILIZING NANOPARTICLES FOR ATO DELIVERY
In addition to the chemical properties and encapsulation strategies of DDSs for ATO, the benefits which the ATO‐
formulations offer are of great interest too. The most recent studies dealing with ATO‐NPs can be assigned to five
categories regarding the benefit(s) which the nanoparticle formulation(s) is/are supposed to yield:
• Improvement of pharmacokinetics,
• Targeted delivery via surface modification,
• Theragnostic properties,
• Enhancement of Transarterial Chemoembolization (TACE), and
• Enhancement of BBB crossing.
4.1 | Improvement of pharmacokinetics
Since improvement of pharmacokinetics—such as controlled release or prolonged blood circulation half‐life—is such
a crucial point when it comes to nanomedicine, almost all studies evaluated dealt with this subject in one way or
another.
4.1.1 | Controlled release of ATO
The most favored approach to achieve controlled release of ATO was to ensure pH‐triggered release from the
respective nanoparticle. Since acidic pH is a well‐known characteristic of tumor tissue,99 making ATO release
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pH‐dependently, with higher ATO release at lower pH value, ought to provide a kind of tumor‐directed ATO
delivery while sparing healthy tissue. pH‐dependent release was achieved mainly through pH‐labile bond respec-
tively attachment between ATO and the nanoparticle.52,59,69–73,75,76,78 Other researchers grafted pH‐responsive
material upon the surface of their nanoparticles to accomplish pH‐dependent ATO release.65,66,68 The degree of
pH‐selective release differed not only depending on the type of nanoparticle used, but on the exact composition of
the respective nanoparticle.
Inorganic phosphate (Pi‐)triggered ATO release was another way of obtaining controllable release. All four
studies following this approach60–62,93 used gadolinium‐based nanoparticles, in which the arsenic could be ex-
changed by phosphate ions. Chen et al.60 reported an outstanding ON/OFF specificity for their GdAsOx nano-
particles, with no arsenic release in the absence of Pi in vitro. Fu et al.61 and Zhao et al.62 attempted to introduce
Pi‐triggered ATO drug‐eluting beats (DEBs) for the improvement of TACE therapy (see below) for HCC. As
occlusion of the hepatic artery is a key characteristic of TACE, and intracellular Pi supply is limited upon occlusion,
the Pi deprivation slowed down the drug release, avoiding high plasma peak levels of arsenic within the first hours
of treatment compared to ATO alone.62,93 Of note is that none of the studies testing for disturbance of Pi levels in
plasma observed lasting changes of the very same.60,93
4.1.2 | Prolonged blood circulation and sustained release of ATO
In comparison to controlled release that is mediated by a defined trigger, sustained release of ATO eventually aims
to prolong the circulation of ATO, allowing sufficient ATO concentrations to reach the tumor site before being
metabolized and excreted. Controlled release can also lead to or be accompanied by sustained release. Zhao et al.73
coated their pH‐sensitive, ATO‐containing HSNs with GSH and observed a higher retention time in blood, which
they attributed to reduced interactions between the GSH‐coated nanoparticles and serum proteins. Zhang et al.68
observed that modifying their nanoparticles with pHLIP not only lead to pH‐dependent release of ATO but also
prolonged nanoparticle blood circulation in mice. Similar observations were made by Tao et al.66 as well as by Xiao
et al.,65 that both grafted their nanoparticles with the pH‐responsive PAA. The in vivo half‐life of those PAA‐coated
nanoparticles was significantly prolonged compared with free ATO.65,66
Independent from pH‐dependency, Lian et al.58 achieved sustained release in vitro by camouflaging their ATO‐
loaded SANs with RBCM. As RBCM coating reduced the macrophage uptake in vitro and showed higher antitumor
effect in vivo, the authors hypothesized that RBCM‐SANs could escape the clearance by the immune system,
enabling more ATO to reach the tumor site.58 Two authors used RGD‐conjugated nanoparticles as a targeted
delivery system (see below) and observed sustained release, namely an enhanced half‐time of ATO in vivo com-
pared to uncoated nanoparticles and free ATO.59,74
Coating with PEG can reduce the uptake of nanoparticles by the reticuloendothelial system, nanoparticle
accumulation in the liver and thereby increase the circulation lifetime.100,101 Several authors verified sustained ATO
release for PEGylated ATO‐loaded nanoparticles in vitro as well as in vivo.55,59,75,76
4.1.3 | Enhanced ATO uptake by tumor cells
A manner of achieving favorable drug distribution in vivo is to obtain enhanced uptake of a drug by tumor cells. This
could be achieved by modifying the surface of nanoparticles with specific targeting ligands56,59,63,66,74 (see below).
By contrast, Chen et al.60 achieved enhanced arsenic accumulation in the tumor via a different mechanism. Their
Pi‐triggered nanoparticles showed a 10‐fold accumulation of arsenic in the tumor tissue compared to free ATO,
which they ascribed to the EPR effect of nanoparticles.60 The EPR effect was also considered a reason for enhanced
uptake of ATO‐NPs in the tumor tissue observed by Tao et al.66 and Huang et al.69 Another nanoparticle system by
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Chi et al.72 lead to almost doubled arsenic uptake compared with free ATO into HCC cells, which the authors
speculated might have been due to the rampant metabolism of tumor cells or easier internalization of nanoparticles
via endocytosis.72 Endocytosis was also identified as the most probable mechanism for enhanced uptake of arsenic
from ATO‐NPs compared with free ATO by Hu et al.55; likewise, they observed a doubling of arsenic concentration.
A similar increase of arsenic accumulation could be observed by Fu et al.,93 in whose study the arsenic level in rabbit
VX2 tumors (a model for human HCC) was almost three times higher under treatment with ATO‐NPs compared to
free ATO. Long‐term accumulation was described in a study by Zhao et al.,62 who showed that with their nano-
particles used in the TACE procedure, intratumoral arsenic could be detected as long as seven days after the TACE
procedure. Free ATO in turn was close to zero after the same time.62 The enhanced uptake of arsenic into HCC
cells in the study of Zhang et al.68 showed pH‐dependency, wherefore the authors ascribed the accumulation in
tumor cells to the pH‐triggered release properties of their nanoparticles.
4.2 | Targeted delivery via surface modification
A huge advantage of nanoparticles consists in their modifiable surface. In the past few years, several studies have
shown, for instance, that chemical modification not only enabled nanoparticles to increase BBB penetration (see
below), but also tuned the toxicity of nanoparticles as drug delivery vehicles.59 Apart from general diversification of
nanoparticle characteristics, surface modification of nanoparticles holds great potential in terms of targeted ther-
apy. Attaching targeting ligands directed towards specific structures on tumor cells or the tumor microenvironment
could possibly lead to an enhanced antitumor effect while sparing healthy tissue.
Recently, three studies evaluated nanoparticles modified with RGD for targeted delivery of ATO towards
glioma, HCC, and TNBC cells.59,63,74 RGD selectively binds αvβ3 integrin peptides, which are overexpressed by
endothelial cells of the tumor vasculature and tumor cells.102 Indeed, the authors showed that the tumor uptake of
RGD‐modified nanoparticles was higher compared to uncoated nanoparticles, which was accompanied by higher
antitumor efficacy, namely lower tumor volume, larger area of tumor necrosis in vivo59,63,74 and longer survival59,74
compared with uncoated ATO‐NPs and ATO alone. Beyond that, Fei et al.74 confirmed that the transport of their
RGD‐modified nanoparticles was effectively dependent on αvβ3 integrins.
Another targeting ligand, lactobionic acid, was studied as a coating agent by Song et al. for HCC‐directed ATO‐
NPs. Lactobionic acid is a disaccharide consisting of gluconic acid and galactose. Galactose‐binding asialoglyco-
protein receptor (ASGPR) is a receptor primarily expressed in the liver and not in other human tissues, therefore it
constitutes an interesting target for HCC‐directed drug delivery.103 The authors showed for two different nano-
particle compositions that surface modification with lactobionic acid led to a decreased toxicity of ATO‐NPs in
normal hepatocytes in comparison to the toxic effect in HCC cells in vitro.56,57 However, in vivo, only minimal
reduction of tumor volume upon treatment with lactobionic acid‐modified ATO‐NPs could be detected compared
with ATO alone. The authors predicated the advantage of lactobionic acid‐modified nanoparticles in sparing the
healthy tissue compared to free ATO, as confirmed by H&E staining of the liver and kidney.57 It is of note that the
preference for HCC cells is ought to be at least partly mediated by the EPR effect as ASGPR is not only expressed
on HCC cells but on normal hepatocytes as well.103
Folic acid is yet another targeting ligand that aims at a receptor which is overexpressed on the surface of
various cancers and has hence been identified as an attractive target for tumor‐directed therapy: the folate receptor
(see Assaraf et al.104 for a review). Chi et al.67 modified their HCC‐directed nanoparticles with folic acid and
observed enhanced in vitro toxicity, as well as enhanced apoptosis induction in HCC cells and improved in vivo
tumor efficacy compared to unmodified nanoparticles and ATO alone.
Zhang et al.52 used a different approach and targeted a structure, which is restricted to the inner membrane of
viable, healthy cells but present on the outer membrane leaflet of numerous cancers: phosphatidylserine (PS). They
bound F(ab')2 fragments of PGN635, a novel human monoclonal PS‐targeting antibody, onto the surface of their
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liposomal ATO‐NPs to target glioma cells. Their in vitro study revealed that nanoparticle binding to glioma cells was
PS‐dependent.52 However, in vivo experiments of this approach are still pending.
Finally, Tao et al.66 modified their nanoparticles with angiopep‐2, a specific ligand of the lipoprotein receptor‐
related protein (LRP) receptor. As Glioma and normal brain endothelial cells express LRP receptor on their surface,
the authors proposed that functionalization of the nanoparticle surface with angiopep‐2 could lead to increased
accumulation of ATO in glioma. As a matter of fact, they verified that angiopep‐2‐modification led to a higher
cellular uptake of nanoparticles by glioma and brain endothelial cells. The study revealed that targeted therapy with
angiopep‐2 was effective in vivo as it was shown by significantly decreased tumor volume, longer survival time and
higher accumulation of the nanoparticles in tumor tissue.
4.3 | Theragnostic properties
Theragnostics describes the combination of therapy and diagnostics in one system. Visualization of drug‐containing
nanoparticles by integrating imaging agents into the nanoparticles is an attractive feature as it allows for image‐
monitored drug delivery. When it comes to theragnostic properties of ATO‐NPs, two imaging agents prevailed the
research: manganese and (superpara)magnetic iron oxide nanoparticles. Both can be detected by MRI.
Zhang et al.52 examined liposomes consisting of arsenite and manganese ions, which were visible as dark
contrast onT2‐weighted MRI imagines. Upon pH‐triggered release of arsenite and manganese, liberated manganese
ions caused a bright signal in T1‐weighted MRI, visualizing not only the location of nanoparticles but the release of
ATO from those nanoparticles.52 A different working group also made use of the fact that the release of manganese
ions from their nanoparticles was proportional to the amount of released arsenic ions. They likewise observed
brightening of theT1 signal, which they confirmed in vivo by conducting MRI before and at several time points after
nanoparticle‐administration in mice. This time‐dependent enhancement of the T1 signal enabled real‐time mon-
itoring of ATO release.68,73 Even though the manganese containing nanoparticles showed good in vitro52 re-
spectively in vivo68,73 biocompatibility in the studies conducted, the toxic effects of free manganese demand
further attention regarding tissue accumulation and long term effects.
In contrast to the bright T1‐imaging contrast manganese, iron oxide displays negative enhancement in
T2‐weighted MRI. Ettlinger et al.
77 as well as Chi et al.67 confirmed that nanoparticles with (superpara)magnetic iron
oxide cores could be visualized via MRI. While the biocompatibility of magnetic iron oxide nanoparticles seems to
be given,105 further studies evaluating the in vivo distribution of ATO‐NPs with iron oxide cores upon intravenous
administration are pending.
4.4 | Enhancement of TACE for HCC treatment
For patients with intermediate‐stage HCC, TACE has become a core treatment method. The method combines
intra‐arterial injection of a chemotherapeutic substance with embolization of tumor feeding vessels.106 In a ran-
domized trial, it could be demonstrated that TACE using drug‐eluting beads (DEB‐TACE) leads to a better tumor
response with reduced adverse side effects compared with normal TACE.107 HCC has been the tumor entity
prevailing the most recent studies on ATO nanoparticles for drug delivery (see Tables 1 and 2). Therefore, it is only
logical that certain studies focused on assessing the value of ATO‐nano DEBs (ATO‐NDEBs) for TACE. The studies
by Fu et al.93 and Zhao et al.62 both focused on ATO‐NDEBs from which ATO could be released in a Pi‐triggered
manner (see above). While Fu et al.93 emulsified their ATO‐NPs in lipiodol, which is also used for conventional
TACE, Zhao et al.62 coated their ATO‐NPs with dextran. Both authors administered their ATO‐NDEBs intra‐
arterially into VX2‐tumor‐bearing rabbits. They observed high intratumoral arsenic accumulation (see above) and
low plasma arsenic levels compared with conventional TACE, indicating that the NDEB formulation prevented the
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rushing out effect of ATO into the peripheral circulation.62,93 Moreover, it was demonstrated that the liver and
renal toxicity of ATO‐NDEB was close to the sham group and much lower than the toxicity of conventional TACE
with ATO, confirmed by H&E staining and blood levels of liver and kidney markers.93
4.5 | Enhancement of BBB crossing
The second most prevalent tumor entity used in the evaluation of nanoparticle‐based drug delivery of ATO are
brain tumors, namely glioma and ATRT (see Tables 1 and 2). As mentioned before, ATO has been shown to be a
potent GLI‐inhibitor (see above). GLI has been firstly identified to be amplified in human malignant glioma.108 What
is more, a subgroup of ATRT is characterized by an overexpression of GLI.109 The desire to improve the char-
acteristics of this potentially effective drug by nanoparticle encapsulation is therefore very reasonable. When it
comes to brain tumors, the BBB constitutes a limiting factor to successful treatment as most drugs cannot pass it
(see Pardridge110 for a review). This problem has been addressed by evaluating ATO‐NPs for transport across the
BBB. While both studies showed higher BBB penetration of their modified ATO‐NPs in vitro as well as higher
antitumor efficacy in vivo,59,66 the strategies differed. Tao et al.66 used angiopep‐2 as a targeting ligand for LRP
receptors, present on both glioma as well as human brain endothelial cells (see above). The competition essay
showed that transport of the NPs across the in vitro BBB model veritably relied on the targeting angiopep‐2.
Lu et al.59 in turn coated their ATO‐NPs with RGDyC, which is known to interact with integrin receptors expressed
on the surface of neutrophils and monocytes.111 The underlying idea was to target leukocytes in peripheral blood,
stimulating phagocytosis of NPs and eventually enabling uptake into the brain across the BBB upon leukocyte
recruitment.59,111 Indeed, their ATO‐NPs showed higher efficacy in vivo, but also decreased the cell viability of
glioma cells in an in vitro BBB model. The leukocyte targeting therefore cannot be the only explanation for
enhanced BBB uptake, which might at least partly be also attributable to the additional PEGylation the authors
used. However, the exact mechanisms of RGDyC‐mediated BBB crossing remain to be elucidated.
5 | CONCLUSION AND OUTLOOK
Evidently, the interest in evaluating nanomedicine for ATO delivery to solid tumors has emerged in the last years,
especially for HCC and brain tumors. There are many aspects to consider when designing nanocarriers for ATO
delivery. It is not just about the loading capacity, but also suitable carrier size, surface properties including an
attachment of targeting ligands, options of triggered drug release or combination with imaging agents to form
theragnostics. Encouragingly, more and more researchers have taken their nanoparticles to the in vivo stage,
supposedly providing a better approximation to the efficacy of NPs than cell culture experiments. However, more
data about biodistribution, in vivo safety and stability of NPs have to be gathered before ATO‐NPs can be taken to
the clinical stage. Given the numerous advances and attempts that have been made in the past few years, we hope
that this review can provide an impetus and inspiration for future research on ATO‐NPs.
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